Search results
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration...
Morningstar· 2 days agoBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration</ ...
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe US Food and Drug Administration (FDA) has granted accelerated approval for Bristol Myers Squibb...
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
Morningstar· 1 day agoBristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR-T cell ...
US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
AOL· 2 days agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat ...
Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug
Investor's Business Daily· 3 days agoStill, aficamten could face a Risk Evaluation and Mitigation Strategy, a Food and Drug ...
Erasca restructures; Novartis moves to complete MorphoSys deal
BioPharma Dive via Yahoo Finance· 10 hours agoThe cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere,...
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
Pharmaceutical Technology via Yahoo Finance· 4 days agoZai Lab has an exclusive license to develop and commercialise the therapy in Greater China....
Immunotherapy may boost survival after lung cancer surgery
UPI· 1 day agoImmunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when...
Biogen Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Investor's Business Daily· 2 days agoThe companies are submitting information on a rolling basis for approval of an under-the-skin...
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
BioPharma Dive via Yahoo Finance· 5 days agoGoldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be...